Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
Marinelli D, Gallina FT, Pannunzio S, Di Civita MA, Torchia A, Giusti R, Gelibter AJ, Roberto M, Verrico M, Melis E, Tajè R, Cecere FL, Landi L, Nisticò P, Porciello N, Occhipinti M, Brambilla M, Forde PM, Liu SV, Botticelli A, Novello S, Ciliberto G, Cortesi E, Facciolo F, Cappuzzo F, Santini D. Marinelli D, et al. Among authors: landi l. Crit Rev Oncol Hematol. 2023 Dec;192:104190. doi: 10.1016/j.critrevonc.2023.104190. Epub 2023 Oct 21. Crit Rev Oncol Hematol. 2023. PMID: 37871779 Free article.
HER2 and lung cancer.
Landi L, Cappuzzo F. Landi L, et al. Expert Rev Anticancer Ther. 2013 Oct;13(10):1219-28. doi: 10.1586/14737140.2013.846830. Expert Rev Anticancer Ther. 2013. PMID: 24134423 Review.
Protein kinase inhibitors to treat non-small-cell lung cancer.
Minuti G, D'Incecco A, Landi L, Cappuzzo F. Minuti G, et al. Among authors: landi l. Expert Opin Pharmacother. 2014 Jun;15(9):1203-13. doi: 10.1517/14656566.2014.909412. Epub 2014 Apr 19. Expert Opin Pharmacother. 2014. PMID: 24745764 Review.
Pharmacotherapy targeting the EGFR oncogene in NSCLC.
Landi L, Cappuzzo F. Landi L, et al. Expert Opin Pharmacother. 2014 Nov;15(16):2293-305. doi: 10.1517/14656566.2014.957179. Epub 2014 Sep 13. Expert Opin Pharmacother. 2014. PMID: 25219817 Review.
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F. Landi L, et al. Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16. Clin Lung Cancer. 2014. PMID: 25242668 Free article.
319 results